Physician profile
Brian Patrick Olofsson
NPI 1073604534
$8,590.00
in general payments reported to CMS, 2019-2025
41 companies · $692 in 2025
The $692 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $1,306 · 2021: $1,569 · 2022: $1,307 · 2023: $994 · 2024: $1,397 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,186.25 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $877.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $735.42 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $714.59 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.58 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $465.18 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $453.68 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $337.55 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $269.01 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $239.91 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $198.10 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.37 | 2020-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $145.71 | 2019-2024 | Eliquis |
| Corcept Therapeutics | $140.24 | 2022-2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $115.44 | 2022-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Olofsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.